The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
Open accessAbstract
Summary: Total therapy 3 incorporated bortezomib into a melphalan‐based tandem transplant regimen for 303 newly diagnosed patients with myeloma. Induction chemotherapy prior to and consolidation chemotherapy after transplants each consisted of two cycles of VTD‐PACE (bortezomib, thalidomide, dexamethasone and 4‐d continuous infusions of cis‐platin, doxorubicin, cyclophosphamide, etoposide); 3‐year maintenance comprised monthly cycles of VTD in the first and TD in the remaining years. The median age was 59 years (age >64 years, 28%). A minimum of 20 × 10 6 CD34 cells/kg was collected in 87% of patients; 83% completed both transplants, and only 5% suffered a treatment‐related death. At 24 months, 83% had achieved near‐complete remission, which was sustained in 88% at 2 years from its onset. With a median follow‐up of 20 months, 2‐year estimates of event‐free and overall survival were 84% and 86% respectively. The 44 patients who experienced an event more often had a high‐risk gene array profile, cytogenetic abnormalities and indicators of high lactate dehydrogenase, beta‐2‐microglobulin, creatinine and International Staging System stage. Toxicities of grade > 2 included thrombo‐embolic events in 27% and peripheral neuropathy in 12%. Results of this phase‐2 study demonstrated that bortezomib could be safely combined with multi‐agent chemotherapy, effecting near‐complete remission status and 2‐year survival rates in more than 80% of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Self-citationHigh-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2817 · Cited by 648
Research works printed but not linked: 29
- 10.1056/NEJM199607113350204 · DOI · Paper page
- 10.1172/JCI112033 · DOI
- 10.1182/blood.V98.2.492 · DOI · Paper page
- 10.1182/blood-2003-04-1045 · DOI · Paper page
- 10.1056/NEJMoa053583 · DOI · Paper page
- 10.1046/j.1365-2141.1998.00930.x · DOI · Paper page
- 10.1182/blood-2005-02-0522 · DOI · Paper page
- Cox D.R., 1972, Regression tables and life tables, Journal of the Royal Statistical Society B, 34, 187, 10.1111/j.2517-6161.1972.tb00899.x · DOI · Paper page
- Facon T., 2006, Superiority of melphalan‐prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma [abstract], Journal of Clinical Oncology, 24, 18S, 10.1200/jco.2006.24.18_suppl.1 · doi:10.1200/jco.2006.24.18_suppl.1
- 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O · DOI · Paper page
- 10.1038/nrc952 · DOI · Paper page
- 10.1111/j.1365-2141.2005.05540.x · DOI · Paper page
- 10.1080/01621459.1958.10501452 · DOI · Paper page
- 10.1200/JCO.2003.01.055 · DOI · Paper page
- 10.1182/blood-2006-04-019778 · DOI · Paper page
- 10.1182/blood-2004-07-2911 · DOI · Paper page
- 10.1016/S0140-6736(06)68338-4 · DOI · Paper page
- Palumbo A., 2006, Oral revlimid plus melphalan and prednisone (R‐MP) for newly diagnosed multiple myeloma: results of a multicenter phase I/II study, Blood, 108, 240a, 10.1182/blood.V108.11.800.800 · doi:10.1182/blood.v108.11.800.800
- 10.1182/blood-2006-08-042275 · DOI · Paper page
- 10.1111/j.1365-2141.2006.06441.x · DOI
- 10.1200/JCO.2002.02.116 · DOI · Paper page
- 10.1056/NEJMoa030288 · DOI · Paper page
- Richardson ???, 2006, Lenalidomide plus bortezomib (Rev‐Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter Phase 1 trial. [abstract], Blood, 108, 124a
- 10.1016/0165-4608(94)00284-I · DOI · Paper page
- Shaughnessy J., 2006, A validated gene expression model of high‐risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1, Blood, 10.1182/blood.V108.11.111.111 · doi:10.1182/blood.v108.11.111.111
- Wang M., 2005, Rapid control of previously untreated multiple myeloma with bortezomib‐thalidomide‐dexamethasone followed by early intensive therapy, Blood, 106, 231a
- 10.1182/blood.V99.5.1745 · DOI · Paper page
- 10.1182/blood-2005-11-013458 · DOI · Paper page
- 10.1182/blood-2006-07-037077 · DOI · Paper page
Cited by
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
Sonneveld, P., Schmidt-Wolf, I. G. H., van der Holt, B., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Vellenga, E., Broyl, A., Blau, I. W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.6820 · Cited by 824
Multiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 789
Kumar, S. K., Mikhael, J. R., Buadi, F. K., Dingli, D., Dispenzieri, A., Fonseca, R., Gertz, M. A., Greipp, P. R., Hayman, S. R., Kyle, R. A., et al. (2009) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0603 · Cited by 628
Metadata
- Authors
- Barlogie, B., Anaissie, E., Van Rhee, F., Haessler, J., Hollmig, K., Pineda‐Roman, M., Cottler‐Fox, M., Mohiuddin, A., Alsayed, Y., Tricot, G., Bolejack, V., Zangari, M., Epstein, J., Petty, N., Steward, D., Jenkins, B., Gurley, J., Sullivan, E., Crowley, J., & Shaughnessy, J. D.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2007-06-22
- Volume
- 138
- Issue
- 2
- Pages
- 176-185
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2011871138
- Cited by
- 331
- References
- 5
- FWCI
- 17.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. https://app.cochat.ai/papers/10.1111/j.1365-2141.2007.06639.x
- The paper
- Barlogie, B., Anaissie, E., Van Rhee, F., Haessler, J., Hollmig, K., Pineda‐Roman, M., Cottler‐Fox, M., Mohiuddin, A., Alsayed, Y., Tricot, G., Bolejack, V., Zangari, M., Epstein, J., Petty, N., Steward, D., Jenkins, B., Gurley, J., Sullivan, E., Crowley, J., & Shaughnessy, J. D. (2007). Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2007.06639.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
